Achieving “State Zero”: New Data on Bimekizumab, Other IL-17is, Transform PsA Treatment Goals, with Philip Mease, MD Philip J. Mease, MD

Published Date: 21 Nov 2025

Mease discussed the latest updates on bimekizumab, sonelokimab, and izokibep at ACR Convergence 2025.

Read Full News

Todays Updates


5 Psychiatry Headlines You Missed in September 2026


5 Psychiatry Headlines You Missed in September 2026

Givinostat Data Point to Delayed Loss of Ambulation, Preserved Muscle Tissue in DMD Isabella Ciccone, MPH


An updated open-label extension analysis and new MRI data from the phase 3 EPIDYS trial, presented at the 2026 AANEM Annual Meeting, add to the evidence for givinostat's long-term effects on disease progression.

Nipocalimab’s Safety Profile Slightly Favored Over Other Myasthenia Gravis Therapies, Indirect Comparison Shows Marco Meglio


A new Bayesian network meta-analysis found nipocalimab's serious adverse event rates compared favorably with other gMG therapies, while overall adverse event rates were comparable.

Early Spinal Muscular Atrophy Treatment Tied to Milder Pediatric Phenotype Marco Meglio


New data from a Cure SMA survey showed that children treated with disease-modifying therapy soon after birth walk more often and have fewer comorbidities than those treated later.

NeurologyLive® Brain Games: October 4, 2026 Louie Pasculli


Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is the history of MDS!

Exocrine Pancreatic Insufficiency Estimated in 40% of Chronic Pancreatitis


Exocrine Pancreatic Insufficiency Estimated in 40% of Chronic Pancreatitis

Corticosteroid Stewardship in Dermatology is Not Steroid Avoidance, With Adam Friedman, MD Adam Friedman, MD, FAAD


Friedman outlines how dermatologists can track cumulative corticosteroid exposure, identify at-risk patients, and improve patient adherence with handouts.

Todays Updates


5 Psychiatry Headlines You Missed in September 2026


5 Psychiatry Headlines You Missed in September 2026

Givinostat Data Point to Delayed Loss of Ambulation, Preserved Muscle Tissue in DMD Isabella Ciccone, MPH


An updated open-label extension analysis and new MRI data from the phase 3 EPIDYS trial, presented at the 2026 AANEM Annual Meeting, add to the evidence for givinostat's long-term effects on disease progression.

Nipocalimab’s Safety Profile Slightly Favored Over Other Myasthenia Gravis Therapies, Indirect Comparison Shows Marco Meglio


A new Bayesian network meta-analysis found nipocalimab's serious adverse event rates compared favorably with other gMG therapies, while overall adverse event rates were comparable.

Early Spinal Muscular Atrophy Treatment Tied to Milder Pediatric Phenotype Marco Meglio


New data from a Cure SMA survey showed that children treated with disease-modifying therapy soon after birth walk more often and have fewer comorbidities than those treated later.

NeurologyLive® Brain Games: October 4, 2026 Louie Pasculli


Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is the history of MDS!

Exocrine Pancreatic Insufficiency Estimated in 40% of Chronic Pancreatitis


Exocrine Pancreatic Insufficiency Estimated in 40% of Chronic Pancreatitis

Corticosteroid Stewardship in Dermatology is Not Steroid Avoidance, With Adam Friedman, MD Adam Friedman, MD, FAAD


Friedman outlines how dermatologists can track cumulative corticosteroid exposure, identify at-risk patients, and improve patient adherence with handouts.

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

The risk of lung cancer recurrence is linked to hypoxemia brought on by sleep apnea.

2.

Cancer patients with HIV have demonstrated safety with immune checkpoint inhibitors.

3.

When Healthcare Chatbots Fall Short of Human Connection

4.

These Athletes Weren't Doping. Their Genes Made It Look Like They Did.

5.

Cancer deaths expected to rise to over 18 million in 2050, nearly 75% more than in 2024


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot